Identification of Prognostic Parameters in Patients With " Senile "

Status Recruiting

Clinical Trial Summary

The aging of the population is a reality in our society, with a strong increase in the number of elderly patients hospitalized for heart failure in our institutions. Heart failure in these patients is more present than to younger patients, with preserved ejection fraction form (HFpEF). Aging is responsible for the onset of senile amyloid cardiomyopathy. This pathology is still imperfectly understood and its link with the increase in the frequency of HFpEF is important. In addition, specific treatments have just shown their effectiveness. It is therefore urgent to better identify the prognostic predictive parameters of this cardiomyopathy. The pathophysiological involvement of the coronary microcirculation responsible for a true microvascular coronary disease (CMVD) has been described as predictive factor in all cardiomyopathies. However the implementation of preventive strategies and / or therapeutic of the coronary microcirculation dysfunction are limited because we lack of diagnostic tests available and applicable to large cohorts of patients. Our team INSERM U1039 Radiopharmaceutiques Biocliniques in collaboration with the laboratory GIPSA-lab (Grenoble Images Speech Signal Automatique), laboratory specialized in the signal analysis, has developed a new method of analysis allowing to measure the coronary microcirculation dysfunction usable in SPECT thanks to the measurement of a myocardial perfusion heterogeneity index (IHPM) (patented technique). The 3C registry (NCT03479580) is a registry studying the prevalence and cardiovascular prognosis of macro and microcirculatory coronary artery disease using the latest coronary evaluation techniques in patient with cardiomyopathy. This registry deployed on interventional cardiology centers on the Alpine Arc is therefore also addressed to patients with senile cardiomyopathy. The data collected will provide a better understanding of the factors influencing the prognosis of senile cardiomyopathy and the prognostic contribution of the measurement of the IHPM will be evaluated.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04225754
Study type	Observational
Source	University Hospital, Grenoble
Contact	Charlotte Casset, Dr
Phone	+33476763627
Email	ccasset@chu-grenoble.fr
Status	Recruiting
Phase
Start date	July 21, 2020
Completion date	August 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04459169` - Cardiac Amyloidosis : Diagnostic Using Red Flag Signals
Recruiting	`NCT03029026` - The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
Recruiting	`NCT06034405` - Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Recruiting	`NCT04915235` - Prevalence and Prognosis of Cardiac Amiloidosis in Turkey
Recruiting	`NCT02966522` - Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis	Phase 2
Terminated	`NCT03333551` - Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy	Phase 4
Recruiting	`NCT04105634` - Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT	Early Phase 1
Recruiting	`NCT05139797` - Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
Not yet recruiting	`NCT05593679` - A Multi-center Cardiac PYP Scan Registry in Taiwan.
Not yet recruiting	`NCT04146415` - Diagnosis of Cardiac Amyloidosis With 99mTc-PYP; Comparison Between Planar Imaging, SPECT/CT and Cardiac-dedicated CZT Camera	N/A
Not yet recruiting	`NCT06427304` - Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure
Recruiting	`NCT06469372` - Cardiac Amyloidosis Discovery Trial	N/A
Recruiting	`NCT04856267` - Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders
Completed	`NCT03119558` - PET/MRI Evaluation of Cardiac Amyloid	Early Phase 1
Recruiting	`NCT02798705` - Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis
Not yet recruiting	`NCT04387344` - Morpho-functional Cardiac Modifications in Treated Mutated Transthyretin Cardiac Amyloidosis
Recruiting	`NCT06129656` - Cardiac Amyloidosis Registry of University Hospital Leipzig
Terminated	`NCT01683825` - Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography	Phase 4
Withdrawn	`NCT04363294` - Targeted Testing for ATTR Among Aortic Stenosis Patients-Pilot	N/A
Not yet recruiting	`NCT04661800` - Study of Olfactory Disorders in Patients With Cardiac Amyloidosis	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Identification of Prognostic Parameters in Patients With " Senile " Amyloid Cardiomyopathy — EVAMYLOSE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms